Want to see ENVB full AI Analyst Report?
ENVB Stock Chart & Stats
$1.37
-$0.01(-0.78%)
At close: 4:00 PM EDT
$1.37
-$0.01(-0.78%)
Day’s Range― - ―
52-Week Range$1.17 - $13.25
Previous CloseN/A
Volume62.46K
Average Volume (3M)92.86K
Market Cap
$7.12M
Enterprise Value-$2.79
Total Cash (Recent Filing)$8.30M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.46
Shares Outstanding4,475,884
10 Day Avg. Volume46,360
30 Day Avg. Volume92,859
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.29
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-315
Revenue Forecast (FY)$10.00M
Bulls Say, Bears Say
Bulls Say
Minimal LeverageEffectively no debt limits interest expense and reduces balance-sheet pressure while the company funds research and development. This gives management more flexibility than a highly leveraged biotech, although it does not eliminate the need for future external capital.
Improved Equity BaseThe higher equity base provides stronger capitalization than in 2025 and may improve resilience while candidates advance through development. It supports continued operations, though the company’s history of equity volatility means this benefit must be weighed against potential dilution.
Reduced Historical LossesLower losses than in earlier years suggest some progress in controlling the cost base, an important foundation for a pre-revenue biotechnology company. Continued discipline could extend its development runway, even though the business remains far from breakeven.
Bears Say
No Commercial RevenueA persistent absence of revenue means the company has no commercial sales base to fund research, operations, or future expansion. Until a candidate reaches commercialization or generates partnership income, financial performance remains dependent on development progress and outside capital.
Persistent Cash BurnOngoing operating and free-cash-flow outflows consume resources without revenue offset and increase reliance on financing. The recent re-acceleration in burn can shorten the funding runway, making future capital needs and possible dilution durable risks during clinical development.
Large Ongoing LossesLarge continuing losses and negative gross profit show that the current cost structure is not supported by operating income. This limits internally generated capital for advancing therapeutics and leaves profitability dependent on successful development, commercialization, or a major partnership.
Enveric Biosciences News
ENVB FAQ
What was Enveric Biosciences’s price range in the past 12 months?
Enveric Biosciences lowest stock price was $1.17 and its highest was $13.25 in the past 12 months.
What is Enveric Biosciences’s market cap?
Enveric Biosciences’s market cap is $7.12M.
When is Enveric Biosciences’s upcoming earnings report date?
Enveric Biosciences’s upcoming earnings report date is Nov 12, 2026 which is in 53 days.
How were Enveric Biosciences’s earnings last quarter?
Enveric Biosciences released its earnings results on Aug 14, 2026. The company reported -$0.759 earnings per share for the quarter.
Is Enveric Biosciences overvalued?
According to Wall Street analysts Enveric Biosciences’s price is currently Overvalued.
Does Enveric Biosciences pay dividends?
Enveric Biosciences does not currently pay dividends.
What is Enveric Biosciences’s EPS estimate?
Enveric Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enveric Biosciences have?
Enveric Biosciences has 4,475,884 shares outstanding.
What happened to Enveric Biosciences’s price movement after its last earnings report?
Enveric Biosciences reported an EPS of -$0.759 in its last earnings report. Following the earnings report the stock price went down -3.583%.
Which hedge fund is a major shareholder of Enveric Biosciences?
Currently, no hedge funds are holding shares in ENVB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Enveric Biosciences
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
Technical Analysis
Biodexa Pharmaceuticals
―
―
Indaptus Therapeutics
―
GT Biopharma
―
Artelo Biosciences
―
Ownership Overview
13.67% Insiders
0.18% Mutual Funds
8.03% Other Institutional Investors
76.81% Public Companies and
Individual Investors